Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19 (PROTECT), a Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety Among Asymptomatic to Moderately-severe, Ambulatory Patients

Next Previous
X
Search
Trial Profile

PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19 (PROTECT), a Randomized, Double-blinded, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety Among Asymptomatic to Moderately-severe, Ambulatory Patients

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Galactomannan (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Registrational; Therapeutic Use
  • Acronyms PROTECT
  • Sponsors BioXyTran

    • Most Recent Events

    • 21 Feb 2024 According to a BioXyTran media release, company intends to use the dose optimization trial data to inform the design of the Phase 3 registrational trial in India, while also adhering to the FDA's request for additional data.
    • 08 Aug 2023 Status changed from not yet recruiting to recruiting, according to a BioXyTran media release.
    • 08 Aug 2023 According to a BioXyTran media release, the company is initiating first stage of its registrational trial which is a dose optimization study that will evaluate 3 different dosage levels against a matching placebo arm in a 5-day trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top